tirzepatide tyler Tirzepatide — Provider-Supervised GLP-1 /

Bessette and Anderson found that 89% ( 95% CI, 87.9-90.1), 88.9% (95% CI, 87.8-90) and 90.6% (95% CI, 89.5-91.6) of the cohort met the criteria for treatment with semaglutide, liraglutide (Saxenda, Novo Nordisk) and tirzepatide (Zepbound, Eli Lilly), respectively

This inconsistent coverage makes compounded alternatives appealing for many people

Many patients are pleasantly surprised at how insurance can significantly reduce costs, making branded semaglutide more affordable

Scientific Overview A 4-amino acid synthetic tetrapeptide modeled on pineal gland epithalamin that activates telomerase and modulates circadian gene expression in preclinical and early human studies